Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter
Boxing ropes
Intercept may struggle to explain why Ocaliva should convert to regular approval. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers